SCHEDULE: Deep Track Capital Discloses 6.46% Stake in MoonLake

Deep Track Capital and affiliates have disclosed a passive beneficial ownership of 6.46% in MoonLake Immunotherapeutics' Class A ordinary shares.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin collectively reported beneficial ownership of 4,610,071 Class A ordinary shares of MoonLake Immunotherapeutics.
• This ownership represents 6.46% of the Class A ordinary shares outstanding.
• The calculation is based on 71,373,579 Class A ordinary shares outstanding as of November 5, 2025, as reported in MoonLake's Prospectus.
• The reporting persons share both voting and dispositive power over all 4,610,071 shares.
• The securities were acquired for investment purposes and not with the intent to change or influence control of the issuer, consistent with a passive investment strategy.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a specialized biotech investment firm is generally viewed positively, as it suggests institutional confidence in the company's value and future prospects.

Positives

• A significant stake (6.46%) by a specialized investment firm like Deep Track Capital indicates confidence in MoonLake Immunotherapeutics' long-term prospects.
• The investment is passive, suggesting a belief in the company's current strategy and management without seeking to influence control.

Negatives

• This filing is a disclosure of ownership and does not inherently contain negative financial or operational information about MoonLake Immunotherapeutics.

Risks

• The filing itself does not detail specific risks related to MoonLake Immunotherapeutics' operations or financial health, but rather discloses a significant ownership position.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from MoonLake Immunotherapeutics or the reporting persons regarding the company's future performance.

Industry Context

The disclosure of a significant stake by Deep Track Capital, a firm specializing in biotechnology investments, signals a vote of confidence in MoonLake Immunotherapeutics within the competitive biotech sector. Such filings are common for institutional investors crossing the 5% ownership threshold, indicating a passive investment strategy rather than an activist one.

Comparison to Industry Standards

• Deep Track Capital's investment in MoonLake Immunotherapeutics aligns with typical strategies of specialized biotech funds that identify promising companies in the pharmaceutical and biotechnology space.
• A 6.46% stake is a substantial position for an institutional investor, often indicating a long-term conviction in the company's drug pipeline or market potential, similar to other significant institutional holdings seen in emerging biotech firms.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor like Deep Track Capital can provide stability and potentially attract further institutional interest, positively impacting shareholder confidence.
• Company Management: A large passive investor typically supports current management and strategy, allowing the company to focus on its operational goals without immediate pressure for strategic changes.

Key Dates

Recommendation

The disclosure of a significant passive stake by a reputable biotech investor like Deep Track Capital is a positive signal, indicating institutional confidence. While not a direct catalyst for immediate 'buy' action, it reinforces a 'hold' position for existing investors and suggests potential for future growth, warranting continued monitoring of the company's fundamentals.

Keywords

MoonLake Immunotherapeutics, Deep Track Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Biotechnology, Investment, Institutional Investor, MLTX